Vimarsana
Biggest News Aggregation in the World

Page 13 - Science Summit News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Science Summit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Science Summit Today - Breaking & Trending Today

What happens when artificial intelligence meets the plain people of Ireland? - Vimarsana News

What happens when artificial intelligence meets the plain people of Ireland?

Anyone who knows Pat Kenny knows that he loves a bit of science, a subject on which he has vast expertise.

Acceleware : Quarterly Report - MD&A (Q3 - 2023) -November 23, 2023 at 03:28 pm EST - Vimarsana News

Acceleware : Quarterly Report - MD&A (Q3 - 2023) -November 23, 2023 at 03:28 pm EST

ACCELEWARE LTD. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 ...

Report details science on enteric methane solutions - Vimarsana News

Report details science on enteric methane solutions

While report points out gene editing as a future possibility, feed additives seem to be the most practical solution right now.

Increased Understanding of the Mechanisms of Myelofibrosis Helps Usher in New Treatments and Novel Agents - Vimarsana News

Increased Understanding of the Mechanisms of Myelofibrosis Helps Usher in New Treatments and Novel Agents

Gaby Hobbs, MD, discusses how research into the biology of myelofibrosis has propelled the development of novel therapies for this patient population and highlights the role that biomarkers play in the diagnosis, prognosis, and treatment response evaluation for these patients.

Regulatory Decisions and Research Boost Management Strategies for Hematologic Malignancies - Vimarsana News

Regulatory Decisions and Research Boost Management Strategies for Hematologic Malignancies

Andrew Kuykendall, MD, discusses the current role of JAK inhibitors in myelofibrosis, the importance of chronic graft-vs-host disease awareness in patients with myeloid malignancies receiving transplant, and unmet needs for patients with chronic myelomonocytic leukemia.